Michael Hofman

F-18-Fluorothymidine PET for Functional Response Assessment Following Radiation Therapy for Extramedullary Hematopoiesis

Belinda A Campbell, Jason Callahan, Merrole Cole-Sinclair, Michael MacManus, Michael S Hofman

Journal article  |  2021  |  CLINICAL NUCLEAR MEDICINE

ABSTRACT: As a marker of cellular proliferation, 18F-fluorothymidine (FLT) PET can detect the distribution of proliferating hemato..

The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.

Louise Emmett, James Buteau, Nathan Papa, Daniel Moon, James Thompson, Matthew J Roberts, Kris Rasiah, David A Pattison, John Yaxley, Paul Thomas, Anthony C Hutton, Shikha Agrawal, Amer Amin, Alexandar Blazevski, Venu Chalasani, Bao Ho, Andrew Nguyen, Victor Liu, Jonathan Lee, Gemma Sheehan-Dare, et al.

Journal article  |  2021  |  Eur Urol

BACKGROUND: Multiparametric magnetic resonance imaging (MRI) is validated for the detection of clinically significant prostate can..

Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.

Shahneen Sandhu, Christina Guo, Michael S Hofman

Journal article  |  2021  |  J Nucl Med

Despite significant advances in prostate cancer therapeutic development over the last two decades, metastatic prostate cancer rema..

Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics.

Michael S Hofman

Journal article  |  2021  |  J Nucl Med

The Global Reading Room: Nuclear Medicine Imaging of Suspected Paraganglioma.

Michael S Hofman, Lizette Louw, Karel Pacak, David Taïeb

Journal article  |  2021  |  AJR Am J Roentgenol

Advanced prostate cancer experimental radioactive treatment-clinical trial decision making: patient experiences.

Bianca Viljoen, Michael S Hofman, Suzanne K Chambers, Jeff Dunn, Haryana Dhillon, Ian D Davis, Nicholas Ralph

Journal article  |  2021  |  BMJ Support Palliat Care

OBJECTIVES: Nested qualitative studies within clinical trials provide the opportunity to better understand participant experiences..

Targeted radioactive therapy for prostate cancer reply

Michael S Hofman, Shahneen Sandhu, Roslyn J Francis, Ian D Davis, Louise Emmett

Journal article  |  2021  |  LANCET

Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series

Amir Iravani, Catherine Mitchell, Tim Akhurst, Shahneen Sandhu, Michael S Hofman, Rodney J Hicks

Journal article  |  2021  |  CLINICAL GENITOURINARY CANCER

• Molecular imaging targeting the prostate-specific membrane antigen, somatostatin receptor subtype 2, and glycolytic pathway may ..

Perspectives on Cutting-Edge Clinical Trials: A Conversation Between Michael Hofman, Johannes Czernin, and Jérémie Calais.

Michael S Hofman, Jérémie Calais, Johannes Czernin

Journal article  |  2021  |  J Nucl Med

Nomograms to predict outcomes after Lu-177-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

Andrei Gafita, Jeremie Calais, Tristan R Grogan, Boris Hadaschik, Hui Wang, Manuel Weber, Shahneen Sandhu, Clemens Kratochwil, Rouzbeh Esfandiari, Robert Tauber, Anna Zeldin, Hendrik Rathke, Wesley R Armstrong, Andrew Robertson, Pan Thin, Calogero D'Alessandria, Matthew B Rettig, Ebrahim S Delpassand, Uwe Haberkorn, David Elashoff, et al.

Journal article  |  2021  |  LANCET ONCOLOGY

BACKGROUND: Lutetium-177 (177Lu) prostate-specific membrane antigen (177Lu-PSMA) is a novel targeted treatment for patients with m..